Spring is arriving, bringing with it pollen, allergy suffering, and litigation. With a $35 billion allergy market at stake, Johnson & Johnson and GlaxoSmithKline are duking it out over whose products do the best job of treating sniffling, sneezing and stuffy noses.
Four years after executing a $310 million deal to sell Intellikine to Takeda, biotech entrepreneur Troy Wilson is back, springing out of stealth mode with a new company that has a full team, $60 million in financing, a cancer drug in-licensed from Johnson & Johnson and a plan to start mid-stage development with two Phase II studies launching later in the year. And he's done it while working out an OTC listing that puts him in a public market with an eye to moving up to one of the national exchanges.
Johnson & Johnson's DePuy Synthes issued a recall last month for 1,500 inserters of titanium elastic nails distributed in the U.S., which the FDA has just disclosed. The warning was given because the inserter is prone to mechanical failure during surgery such as breakage in the main shaft, a jam in the inserter or breakage of the crossbar.
A month after Genmab and Johnson & Johnson's Janssen released successful mid-stage data for its multiple myeloma antibody daratumumab, Halozyme has jumped on board, planning a Phase I trial with its subcutaneous delivery technology.
The McNeil Consumer Healthcare plant in Pennsylvania where a laissez-faire attitude about quality led Johnson & Johnson into a regulatory quagmire has now led the drugmaker to plead guilty to a federal misdemeanor charge and fork over $25 million.
Johnson & Johnson's McNeil Consumer Healthcare has pleaded guilty to a federal misdemeanor charge and will pay a $20 million fine and forfeit another $5 million for allowing Infants' Tylenol, Children's Tylenol and Children's Motrin products into the market that were tainted with metals.
Mindera, the developer of a microneedle-based molecular diagnostic system for skin cancer, was among the first 10 resident companies at Johnson & Johnson's just-opened JLABS life science incubator in San Francisco. That means that the life science bigwig believes Mindera's technology is novel and of interest to one of the many companies under its umbrella.
Close to the fourth anniversary of Japan's post-tsunami nuclear disaster in Fukushima Prefecture, the government has managed to attract at least three makers of medical devices to join in a global hub in the state.
Johnson & Johnson lost another battle in its ongoing vaginal mesh litigation, as a California jury ordered the company to pay $5.6 million in the first trial over one of its mesh devices.
Boston Scientific advised physicians about a particular pacemaker in 2005--but then declined to pay the bills for those surgeries that it subsequently received from German health insurers. An EU court ruled on March 5 that the company is liable for those costs, according to Reuters.